Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marc S. Traeger is active.

Publication


Featured researches published by Marc S. Traeger.


Emerging Infectious Diseases | 2002

Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings.

Daniel B. Jernigan; Pratima L. Raghunathan; Beth P. Bell; Ross J. Brechner; Eddy A. Bresnitz; Jay C. Butler; Marty Cetron; Mitch Cohen; Timothy J. Doyle; Marc Fischer; Carolyn M. Greene; Kevin S. Griffith; Jeannette Guarner; James L. Hadler; James A. Hayslett; Richard F. Meyer; Lyle R. Petersen; Michael R. Phillips; Robert W. Pinner; Tanja Popovic; Conrad P. Quinn; Jennita Reefhuis; Dori B. Reissman; Nancy E. Rosenstein; Anne Schuchat; Wun-Ju Shieh; Larry Siegal; David L. Swerdlow; Fred C. Tenover; Marc S. Traeger

In October 2001, the first inhalational anthrax case in the United States since 1976 was identified in a media company worker in Florida. A national investigation was initiated to identify additional cases and determine possible exposures to Bacillus anthracis. Surveillance was enhanced through health-care facilities, laboratories, and other means to identify cases, which were defined as clinically compatible illness with laboratory-confirmed B. anthracis infection. From October 4 to November 20, 2001, 22 cases of anthrax (11 inhalational, 11 cutaneous) were identified; 5 of the inhalational cases were fatal. Twenty (91%) case-patients were either mail handlers or were exposed to worksites where contaminated mail was processed or received. B. anthracis isolates from four powder-containing envelopes, 17 specimens from patients, and 106 environmental samples were indistinguishable by molecular subtyping. Illness and death occurred not only at targeted worksites, but also along the path of mail and in other settings. Continued vigilance for cases is needed among health-care providers and members of the public health and law enforcement communities.


Emerging Infectious Diseases | 2002

First Case of Bioterrorism-Related Inhalational Anthrax in the United States, Palm Beach County, Florida, 2001

Marc S. Traeger; Steven Wiersma; Nancy E. Rosenstein; Jean M. Malecki; Colin W. Shepard; Pratima L. Raghunathan; Segaran P. Pillai; Tanja Popovic; Conrad P. Quinn; Richard F. Meyer; Sharif R. Zaki; Savita Kumar; Sherrie M. Bruce; James J. Sejvar; Peter M. Dull; Bruce C. Tierney; Joshua D. Jones; Bradley A. Perkins

On October 4, 2001, we confirmed the first bioterrorism-related anthrax case identified in the United States in a resident of Palm Beach County, Florida. Epidemiologic investigation indicated that exposure occurred at the workplace through intentionally contaminated mail. One additional case of inhalational anthrax was identified from the index patient’s workplace. Among 1,076 nasal cultures performed to assess exposure, Bacillus anthracis was isolated from a co-worker later confirmed as being infected, as well as from an asymptomatic mail-handler in the same workplace. Environmental cultures for B. anthracis showed contamination at the workplace and six county postal facilities. Environmental and nasal swab cultures were useful epidemiologic tools that helped direct the investigation towards the infection source and transmission vehicle. We identified 1,114 persons at risk and offered antimicrobial prophylaxis.


The Journal of Pediatrics | 2015

No Visible Dental Staining in Children Treated with Doxycycline for Suspected Rocky Mountain Spotted Fever

Suzanne R. Todd; F. Scott Dahlgren; Marc S. Traeger; Eugenio D. Beltrán-Aguilar; Donald W. Marianos; Charlene Hamilton; Jennifer H. McQuiston; Joanna J. Regan

OBJECTIVE To evaluate whether cosmetically relevant dental effects occurred among children who had received doxycycline for treatment of suspected Rocky Mountain spotted fever (RMSF). STUDY DESIGN Children who lived on an American Indian reservation with high incidence of RMSF were classified as exposed or unexposed to doxycycline, based on medical and pharmacy record abstraction. Licensed, trained dentists examined each childs teeth and evaluated visible staining patterns and enamel hypoplasia. Objective tooth color was evaluated with a spectrophotometer. RESULTS Fifty-eight children who received an average of 1.8 courses of doxycycline before 8 years of age and who now had exposed permanent teeth erupted were compared with 213 children who had never received doxycycline. No tetracycline-like staining was observed in any of the exposed childrens teeth (0/58, 95% CI 0%-5%), and no significant difference in tooth shade (P=.20) or hypoplasia (P=1.0) was found between the 2 groups. CONCLUSIONS This study failed to demonstrate dental staining, enamel hypoplasia, or tooth color differences among children who received short-term courses of doxycycline at <8 years of age. Healthcare provider confidence in use of doxycycline for suspected RMSF in children may be improved by modifying the drugs label.


Annals of the New York Academy of Sciences | 2006

Rocky Mountain spotted fever in Arizona: documentation of heavy environmental infestations of Rhipicephalus sanguineus at an endemic site.

William L. Nicholson; Christopher D. Paddock; Linda J. Demma; Marc S. Traeger; Brian Johnson; Jeffrey Dickson; Jennifer H. McQuiston; David L. Swerdlow

Abstract:  A recent epidemiologic investigation identified 16 cases and 2 deaths from Rocky Mountain spotted fever (RMSF) in two eastern Arizona communities. Prevalence studies were conducted by collecting free‐living ticks (Acari: Ixodidae) from the home sites of RMSF patients and from other home sites within the community. Dry ice traps and flagging confirmed heavy infestations at many of the home sites. Only Rhipicephalus sanguineus ticks were identified and all developmental stages were detected. It is evident that under certain circumstances, this species does transmit Rickettsia rickettsii to humans and deserves reconsideration as a vector in other geographic areas.


Emerging Infectious Diseases | 2003

Severe Histoplasmosis in Travelers to Nicaragua

Michelle Weinberg; Julia Weeks; Susan Lance-Parker; Marc S. Traeger; Steven Wiersma; Quyen Phan; David Dennison; Pia D.M. MacDonald; Mark D. Lindsley; Jeannette Guarner; Patricia Connolly; Martin S. Cetron; Rana Hajjeh

We investigated an outbreak of unexpectedly severe histoplasmosis among 14 healthy adventure travelers from the United States who visited a bat-infested cave in Nicaragua. Although histoplasmosis has rarely been reported to cause serious illness among travelers, this outbreak demonstrates that cases may be severe among travelers, even young, healthy persons.


Clinical Infectious Diseases | 2015

Risk Factors for Fatal Outcome From Rocky Mountain Spotted Fever in a Highly Endemic Area—Arizona, 2002–2011

Joanna J. Regan; Marc S. Traeger; Dwight Humpherys; Dianna L. Mahoney; Michelle Martinez; Ginny L. Emerson; Danielle M. Tack; Aimee Geissler; Seema Yasmin; Regina Lawson; Velda Williams; Charlene Hamilton; Craig Levy; Ken Komatsu; David A. Yost; Jennifer H. McQuiston

BACKGROUND Rocky Mountain spotted fever (RMSF) is a disease that now causes significant morbidity and mortality on several American Indian reservations in Arizona. Although the disease is treatable, reported RMSF case fatality rates from this region are high (7%) compared to the rest of the nation (<1%), suggesting a need to identify clinical points for intervention. METHODS The first 205 cases from this region were reviewed and fatal RMSF cases were compared to nonfatal cases to determine clinical risk factors for fatal outcome. RESULTS Doxycycline was initiated significantly later in fatal cases (median, day 7) than nonfatal cases (median, day 3), although both groups of case patients presented for care early (median, day 2). Multiple factors increased the risk of doxycycline delay and fatal outcome, such as early symptoms of nausea and diarrhea, history of alcoholism or chronic lung disease, and abnormal laboratory results such as elevated liver aminotransferases. Rash, history of tick bite, thrombocytopenia, and hyponatremia were often absent at initial presentation. CONCLUSIONS Earlier treatment with doxycycline can decrease morbidity and mortality from RMSF in this region. Recognition of risk factors associated with doxycycline delay and fatal outcome, such as early gastrointestinal symptoms and a history of alcoholism or chronic lung disease, may be useful in guiding early treatment decisions. Healthcare providers should have a low threshold for initiating doxycycline whenever treating febrile or potentially septic patients from tribal lands in Arizona, even if an alternative diagnosis seems more likely and classic findings of RMSF are absent.


Clinical Infectious Diseases | 2015

Rocky Mountain Spotted Fever Characterization and Comparison to Similar Illnesses in a Highly Endemic Area—Arizona, 2002–2011

Marc S. Traeger; Joanna J. Regan; Dwight Humpherys; Dianna L. Mahoney; Michelle Martinez; Ginny L. Emerson; Danielle M. Tack; Aimee Geissler; Seema Yasmin; Regina Lawson; Charlene Hamilton; Velda Williams; Craig Levy; Kenneth Komatsu; Jennifer H. McQuiston; David A. Yost

BACKGROUND Rocky Mountain spotted fever (RMSF) has emerged as a significant cause of morbidity and mortality since 2002 on tribal lands in Arizona. The explosive nature of this outbreak and the recognition of an unexpected tick vector, Rhipicephalus sanguineus, prompted an investigation to characterize RMSF in this unique setting and compare RMSF cases to similar illnesses. METHODS We compared medical records of 205 patients with RMSF and 175 with non-RMSF illnesses that prompted RMSF testing during 2002-2011 from 2 Indian reservations in Arizona. RESULTS RMSF cases in Arizona occurred year-round and peaked later (July-September) than RMSF cases reported from other US regions. Cases were younger (median age, 11 years) and reported fever and rash less frequently, compared to cases from other US regions. Fever was present in 81% of cases but not significantly different from that in patients with non-RMSF illnesses. Classic laboratory abnormalities such as low sodium and platelet counts had small and subtle differences between cases and patients with non-RMSF illnesses. Imaging studies reflected the variability and complexity of the illness but proved unhelpful in clarifying the early diagnosis. CONCLUSIONS RMSF epidemiology in this region appears different than RMSF elsewhere in the United States. No specific pattern of signs, symptoms, or laboratory findings occurred with enough frequency to consistently differentiate RMSF from other illnesses. Due to the nonspecific and variable nature of RMSF presentations, clinicians in this region should aggressively treat febrile illnesses and sepsis with doxycycline for suspected RMSF.


American Journal of Tropical Medicine and Hygiene | 2015

Medical and Indirect Costs Associated with a Rocky Mountain Spotted Fever Epidemic in Arizona, 2002–2011

Naomi A. Drexler; Marc S. Traeger; Jennifer H. McQuiston; Velda Williams; Charlene Hamilton; Joanna J. Regan

Rocky Mountain spotted fever (RMSF) is an emerging public health issue on some American Indian reservations in Arizona. RMSF causes an acute febrile illness that, if untreated, can cause severe illness, permanent sequelae requiring lifelong medical support, and death. We describe costs associated with medical care, loss of productivity, and death among cases of RMSF on two American Indian reservations (estimated population 20,000) between 2002 and 2011. Acute medical costs totaled more than


The New England Journal of Medicine | 2005

Rocky Mountain Spotted Fever from an Unexpected Tick Vector in Arizona

Linda J. Demma; Marc S. Traeger; William L. Nicholson; Christopher D. Paddock; Dianna M. Blau; Marina E. Eremeeva; Michael Levin; Joseph Singleton; Sherif R. Zaki; James E. Cheek; David L. Swerdlow; Jennifer H. McQuiston

1.3 million. This study further estimated


Vector-borne and Zoonotic Diseases | 2006

Serologic Evidence for Exposure to Rickettsia rickettsii in Eastern Arizona and Recent Emergence of Rocky Mountain Spotted Fever in This Region

Linda J. Demma; Marc S. Traeger; Dianna M. Blau; Rondeen Gordon; Brian Johnson; Jeff Dickson; Rudy Ethelbah; Stephen Piontkowski; Craig Levy; William L. Nicholson; Christopher Duncan; Karen Heath; James E. Cheek; David L. Swerdlow; Jennifer H. McQuiston

181,100 in acute productivity lost due to illness, and

Collaboration


Dive into the Marc S. Traeger's collaboration.

Top Co-Authors

Avatar

Jennifer H. McQuiston

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Joanna J. Regan

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David L. Swerdlow

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Craig Levy

Arizona Game and Fish Department

View shared research outputs
Top Co-Authors

Avatar

Linda J. Demma

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

William L. Nicholson

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Aimee Geissler

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christopher D. Paddock

Centers for Disease Control and Prevention

View shared research outputs
Researchain Logo
Decentralizing Knowledge